Cobro Ventures

AI Proteins is a biotechnology company founded in 2021 and based in Boston, Massachusetts. The firm specializes in the design and engineering of synthetic mini protein therapeutics through an innovative drug discovery platform. Utilizing artificial intelligence, AI Proteins restructures protein therapeutics by creating synthetic proteins from the ground up, tailored to enhance their activity for various therapeutic applications. This approach allows for the rapid development of lead product candidates, providing clients with proteins that are cost-effective, durable, specific, and optimized for oral delivery.

Regenacy Pharmaceuticals, LLC is a biopharmaceutical company based in Boston, Massachusetts, founded in 2016. The company focuses on developing innovative treatments for peripheral neuropathies, hemoglobinopathies, and certain oncology indications. Its approach centers on the regeneration of normal protein function through the use of oral, isoform-selective histone deacetylase (HDAC) inhibitors. Notably, Regenacy is advancing the selective HDAC6 inhibitor ricolinostat, which has potential applications in treating sickle cell disease and beta-thalassemia. Through its novel, disease-modifying strategies, Regenacy aims to address significant unmet medical needs in these therapeutic areas.

NextRNA Therapeutics is a biotechnology company based in Cambridge, Massachusetts, founded in 2020. The company focuses on developing targeted therapeutics by discovering novel non-coding ribonucleic acids (ncRNAs) linked to various diseases. Utilizing an innovative discovery platform, NextRNA identifies and modulates RNA-binding proteins associated with disease functions of ncRNAs. This approach aims to disrupt the interactions between disease-related ncRNAs and their protein partners, thereby enabling medical practitioners to address and potentially cure a range of diseases.

Windgap Medical Inc. is a biotechnology company that specializes in the manufacture of compact epinephrine autoinjectors designed for the treatment of anaphylaxis, a severe allergic reaction. Established in 2011, the company is headquartered in Watertown, Massachusetts. Windgap Medical's innovative auto-injectors are filled with heat-stable epinephrine, which enhances the temperature resilience and shelf life of the medication. This feature allows healthcare providers to effectively administer epinephrine to patients experiencing acute allergy attacks, improving their chances of recovery during critical moments.

TechsoMed is an Israeli medical device company focused on developing ultrasound-based real-time monitoring systems specifically for thermal ablation procedures. This technology addresses the high failure rates associated with these minimally invasive treatments, which are used in various applications, including tumor destruction, heart arrhythmia management, and blood pressure regulation. By providing real-time monitoring and control of tissue destruction, TechsoMed's system enhances the effectiveness of ablation procedures, offering significant benefits to patients, physicians, and insurance companies. The integration of their imaging and analysis unit with standard ultrasound devices allows physicians to better predict the progression of tissue destruction, thereby improving treatment outcomes in a market that has significant growth potential.

MANA Therapeutics develops innovative cell therapies aimed at providing safe and durable treatments for cancer. The company focuses on harnessing the power of immune cells to combat cancer, with the goal of conferring long-lasting immunity to the disease. By educating endogenous immune cells, MANA Therapeutics enables clinicians to enhance the body’s natural defenses against cancer cells. Their approach not only seeks to eliminate cancer but also emphasizes economic viability, making these therapies accessible and sustainable in the long term. The team comprises dedicated scientists, physicians, and advocates committed to advancing cancer treatment through cutting-edge immune cell education techniques.

Regenacy Pharmaceuticals, LLC is a biopharmaceutical company based in Boston, Massachusetts, founded in 2016. The company focuses on developing innovative treatments for peripheral neuropathies, hemoglobinopathies, and certain oncology indications. Its approach centers on the regeneration of normal protein function through the use of oral, isoform-selective histone deacetylase (HDAC) inhibitors. Notably, Regenacy is advancing the selective HDAC6 inhibitor ricolinostat, which has potential applications in treating sickle cell disease and beta-thalassemia. Through its novel, disease-modifying strategies, Regenacy aims to address significant unmet medical needs in these therapeutic areas.

Frequency Therapeutics is a clinical-stage biotechnology company based in Woburn, Massachusetts, that aims to repair or reverse damage from various degenerative diseases by utilizing the body’s own biological mechanisms. The company employs a Progenitor Cell Activation approach, which involves the use of small molecules to activate progenitor cells and promote the regeneration of functional tissue. Its leading product candidate, FX-322, is currently undergoing phase 2a clinical trials to address the underlying causes of sensorineural hearing loss. In addition to hearing loss, Frequency Therapeutics is also exploring treatments for a range of other conditions, including multiple sclerosis and diseases affecting muscle, the gastrointestinal tract, skin, and bone. The company has established a collaboration with Astellas Pharma for the development and commercialization of FX-322. Founded in 2014, Frequency Therapeutics focuses on disease modification without the complexities associated with genetic engineering.

Frequency Therapeutics is a clinical-stage biotechnology company based in Woburn, Massachusetts, that aims to repair or reverse damage from various degenerative diseases by utilizing the body’s own biological mechanisms. The company employs a Progenitor Cell Activation approach, which involves the use of small molecules to activate progenitor cells and promote the regeneration of functional tissue. Its leading product candidate, FX-322, is currently undergoing phase 2a clinical trials to address the underlying causes of sensorineural hearing loss. In addition to hearing loss, Frequency Therapeutics is also exploring treatments for a range of other conditions, including multiple sclerosis and diseases affecting muscle, the gastrointestinal tract, skin, and bone. The company has established a collaboration with Astellas Pharma for the development and commercialization of FX-322. Founded in 2014, Frequency Therapeutics focuses on disease modification without the complexities associated with genetic engineering.

MANA Therapeutics develops innovative cell therapies aimed at providing safe and durable treatments for cancer. The company focuses on harnessing the power of immune cells to combat cancer, with the goal of conferring long-lasting immunity to the disease. By educating endogenous immune cells, MANA Therapeutics enables clinicians to enhance the body’s natural defenses against cancer cells. Their approach not only seeks to eliminate cancer but also emphasizes economic viability, making these therapies accessible and sustainable in the long term. The team comprises dedicated scientists, physicians, and advocates committed to advancing cancer treatment through cutting-edge immune cell education techniques.

Frequency Therapeutics is a clinical-stage biotechnology company based in Woburn, Massachusetts, that aims to repair or reverse damage from various degenerative diseases by utilizing the body’s own biological mechanisms. The company employs a Progenitor Cell Activation approach, which involves the use of small molecules to activate progenitor cells and promote the regeneration of functional tissue. Its leading product candidate, FX-322, is currently undergoing phase 2a clinical trials to address the underlying causes of sensorineural hearing loss. In addition to hearing loss, Frequency Therapeutics is also exploring treatments for a range of other conditions, including multiple sclerosis and diseases affecting muscle, the gastrointestinal tract, skin, and bone. The company has established a collaboration with Astellas Pharma for the development and commercialization of FX-322. Founded in 2014, Frequency Therapeutics focuses on disease modification without the complexities associated with genetic engineering.

C4 Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative therapeutic candidates that target and eliminate disease-causing proteins, primarily for the treatment of cancer and neurodegenerative disorders. The company's lead product candidate, CFT7455, is an orally bioavailable degrader designed to target IKZF1/3 for multiple myeloma and other lymphomas. Additionally, C4 is advancing CFT8634, which targets BRD9 for specific solid tumors, alongside programs aimed at genetically defined resistant solid tumors. C4 Therapeutics utilizes its proprietary Degronimid platform, which allows for the selective degradation of proteins through the natural ubiquitin/proteasome system, potentially addressing previously undruggable targets while minimizing drug resistance. The company has formed strategic collaborations with major industry players, and it aims to make a significant impact on the treatment landscape through its advanced protein degradation science and multiple development programs. Founded in 2015 and headquartered in Watertown, Massachusetts, C4 Therapeutics continues to innovate in the field of targeted therapy.

Acetylon Pharmaceuticals, Inc. is focused on developing small molecule drugs that target epigenetic mechanisms to improve therapeutic outcomes in cancer and other serious diseases. Established in 2008 and headquartered in Boston, Massachusetts, the company has created a proprietary platform that has led to a portfolio of optimized selective compounds for oral administration, specifically targeting Class I and Class II histone deacetylases. Among its lead drug candidates are ACY-1215 and ACY-241, which are selective HDAC6 inhibitors currently undergoing Phase 2 and Phase 1b clinical trials for the treatment of multiple myeloma. Acetylon Pharmaceuticals operates as a subsidiary of Celgene Corporation, emphasizing its commitment to addressing critical unmet medical needs through innovative epigenetic therapies.

Founded in 1986, OPNET Technologies, Inc. (NASDAQ: OPNT) is a provider of software products and related services for managing networks and applications. Their products by focusing on analytics. Traditional application and network management products focus on data collection and monitoring. These systems typically report on historical trends and the status of networks and systems. They are limited by their lack of understanding of the underlying technologies that support applications, and the relationships among these technologies. While they provide useful information, they do not automate the next important step, which is analyzing collected data to transform it into actionable information. OPNET’s analysis capabilities drive the rapid resolution of performance problems, and also proactively prevent problems from occurring. These problems include, for example, network configuration errors, network congestion, poor interaction between the network and applications, inefficient use of the network by applications, application bugs, and database inefficiencies. They believe that OPNET’s analytics can significantly improve the performance and availability of mission-critical networks and applications.